Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05671835 · ClinicalTrials.gov registry record · Phase 2
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Tvardi Therapeutics, Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT05671835: Completed Phase 2 study, sponsored by Tvardi Therapeutics, Incorporated.
NCT05671835 is a Phase 2 study that has completed, run by Tvardi Therapeutics, Incorporated. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05671835, a Phase 2 study, has completed, sponsored by Tvardi Therapeutics, Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Primary Outcome
Incidence of AEs, including serious AEs assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) V.5.0. Clinically significant changes between baseline and postbaseline laboratory assessments, electrocardiograms, vital signs, and physical examinations will be recorded as AEs.
Interventions
- DRUG Placebo
- DRUG TTI-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2025-08-14 |
| Phase | Phase 2 |
What the finished NCT05671835 record still lists
NCT05671835 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05671835 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05671835 about?
NCT05671835 is a clinical study titled "Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis". The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT05671835?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-05-15. Estimated completion is 2025-08-14.
What interventions are being tested in trial NCT05671835?
The interventions under investigation include: Placebo (DRUG), TTI-101 (DRUG).
Who is sponsoring clinical trial NCT05671835?
This trial is sponsored by Tvardi Therapeutics, Incorporated, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05671835's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI